semaglutide news october 2025 Novo Nordisk further lowers prices for weight loss, diabetes drugs for those who pay cash Novo Nordisk gears up for

The cost barrier is equally structural: at USD 1,000-1,300 per month without insurance, GLP-1 drugs are affordable only to a small fraction of the global population who could benefit clinically, concentrating commercial market growth in the wealthy minority of the total addressable patient population

The Efficacy Question: Pills Aren't Injectables (Yet) Here's where injections still hold clear ground

The middle ground: tirzepatide and combination approaches It is worth noting that a middle option exists

Both Semaglutide and Tirzepatide are FDA-approved for weight loss

If you're a tested athlete, you should also be aware that anti-doping rules can apply: USADA notes BPC-157 is prohibited under WADA's Prohibited List as an "unapproved substance"